These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 39260752

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin.
    Hu X, Dong M, Liang X, Liu Z, Li Q.
    Int J Nanomedicine; 2021; 16():471-480. PubMed ID: 33500617
    [Abstract] [Full Text] [Related]

  • 3. A Novel Long-circulating DOX Liposome: Formulation and Pharmacokinetics Studies.
    Xiao P, Zhao J, Huang Y, Jin R, Tang Z, Wang P, Song X, Zhu H, Yang Z, Yu N.
    Pharm Nanotechnol; 2020; 8(5):391-398. PubMed ID: 32787769
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
    Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.
    Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
    [Abstract] [Full Text] [Related]

  • 6. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K, Kashiwagi M, Shiba S, Muroki K, Ohishi A, Doi Y, Ando H, Ishida T, Nagasawa K.
    Toxicol Appl Pharmacol; 2017 Dec 15; 337():76-84. PubMed ID: 29054682
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.
    Jpn J Clin Oncol; 2006 Dec 15; 36(12):768-74. PubMed ID: 17095524
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
    Xu L, Wang W, Sheng YC, Zheng QS.
    J Clin Pharm Ther; 2010 Oct 15; 35(5):593-601. PubMed ID: 20831683
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
    Ryan GM, Kaminskas LM, Bulitta JB, McIntosh MP, Owen DJ, Porter CJH.
    J Control Release; 2013 Nov 28; 172(1):128-136. PubMed ID: 23954628
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
    Jiang W, Lionberger R, Yu LX.
    Bioanalysis; 2011 Feb 28; 3(3):333-44. PubMed ID: 21320053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.